Three Genetic Loci Modify Risk and Onset of Inherited Alzheimer's Disease

Unraveling Genetic Influences in Inherited Alzheimer's Disease

While the vast majority of Alzheimer's disease cases are sporadic and linked to aging, a small fraction are caused by highly penetrant autosomal dominant mutations in the APP, PSEN1, or PSEN2 genes [1, 2, 3]. Clinicians have long observed, however, that even among individuals with these deterministic mutations, the age of onset and clinical progression can vary significantly [3]. This variability points to the existence of other genetic modifiers that can influence the course of the disease. Identifying these modifiers is critical for a deeper understanding of the biological mechanisms driving amyloid-beta and tau pathologies, and for developing more precise prognostic tools and targeted interventions [2, 4].

Study Design and Participant Cohorts

To investigate the genetic basis for this clinical variability, a recent genome-wide association study analyzed data from three major cohorts: the Knight Alzheimer Disease Research Center (Knight-ADRC), the Dominantly Inherited Alzheimer Network (DIAN), and the Alzheimer Disease Sequencing Project (ADSP) R4. The study's design integrated multiple layers of biological data to build a comprehensive picture of disease modification. The core genetic analysis involved whole-genome sequencing of 101 unrelated, non-Hispanic, White, symptomatic participants with autosomal dominant Alzheimer's disease (ADAD) mutations and 5050 asymptomatic, unrelated controls, with sensitivity analyses expanding this to 148 cases and 5813 controls.

To connect genetic findings to biological mechanisms, the researchers correlated identified risk variants with several downstream measures. These included plasma protein levels from 2338 participants (Knight-ADRC), cerebrospinal fluid (CSF) concentrations of core Alzheimer's biomarkers from 64 participants (DIAN), and neuroimaging data (MRI and PET) from the same 64 DIAN participants. Finally, to assess the relevance beyond inherited forms of the disease, the authors examined the association between the identified variants and age at onset in a large cohort of 6177 participants with sporadic Alzheimer's disease (ADSP R5).

Identification of Three Modifying Genetic Loci

The analysis successfully identified three genetic loci that were significantly associated with ADAD risk, regardless of which primary mutation (PSEN1, PSEN2, or APP) a patient carried. The first locus, CNIH4, was linked to disease risk through a specific missense variant, Gly54Ser. This variant was associated with a nearly 12-fold increase in the odds of developing ADAD (odds ratio [OR] 11.99, 95% CI 5.39-26.64; p<0.0001). A second locus, CCNG1, contained a risk allele that was also strongly associated with disease, increasing the odds by more than nine-fold (OR 9.56, 95% CI 4.29-21.24; p<0.0001).

Beyond simply increasing risk, the CCNG1 allele had a direct impact on the clinical timeline. Carriers of the CCNG1 risk allele experienced dementia onset an average of 10.15 years earlier than non-carriers (β=-10.15, 95% CI -17.31 to -2.77; p=0.0068). This genetic variant was also associated with specific biological changes, including higher plasma levels of Tar DNA binding protein 43 (TDP-43), a protein implicated in other neurodegenerative conditions like frontotemporal dementia and amyotrophic lateral sclerosis. Furthermore, the allele was linked to a larger gap between a patient's chronological age and their brain's structural age as predicted by MRI, a finding that suggests a mechanism of accelerated brain atrophy.

RHOJ Locus and Biomarker Associations

The third significant genetic modifier was found at the RHOJ locus. The risk allele at this location was associated with a nearly six-fold increased risk for Alzheimer's disease (OR 5.96, 95% CI 3.42-10.36; p<0.0001). To understand how this gene might exert its effect, the researchers examined its relationship with established CSF biomarkers in ADAD participants from the DIAN cohort. The findings provided a clear link to the core pathologies of Alzheimer's disease.

Carriers of the RHOJ risk allele exhibited significantly higher levels of CSF total tau (β=358.37; p=0.0056) and phosphorylated tau 181 (pTau181; β=81.28; p=0.0006), both established markers of neuronal injury and the formation of neurofibrillary tangles. In parallel, these individuals showed a significantly lower CSF Aβ42/Aβ40 ratio (β=-0.11; p=0.016). A lower ratio is a classic signature of Alzheimer's pathology, reflecting the sequestration of Aβ42 from the CSF as it aggregates into amyloid plaques within the brain. Together, these biomarker associations suggest the RHOJ allele contributes to disease by exacerbating both amyloid and tau pathologies.

Clinical Implications and Future Directions

These findings provide crucial insights into the complex biology of Alzheimer's disease, highlighting how genetic background can modulate the effects of primary disease-causing mutations. The study implicates pathways involving not only amyloid and tau but also TDP-43, astrocyte function, and angiogenesis, offering new targets for investigation. For practicing physicians, this research has direct implications for patient counseling. For families affected by ADAD, knowledge of a patient's status for these modifying alleles could help refine prognoses. For example, the finding that the CCNG1 allele is associated with a 10.15-year acceleration of dementia onset provides a tangible piece of information for family discussions about life planning and potential clinical trial enrollment.

Furthermore, the identification of these genetic modifiers and their associated biological pathways can inform the design of future clinical trials. Interventions could be developed to target the mechanisms influenced by CNIH4, CCNG1, or RHOJ. Trials could also potentially stratify participants based on their genetic modifier status to test the efficacy of targeted therapies in specific, biologically-defined subgroups of the ADAD population. By moving beyond a one-size-fits-all view of inherited Alzheimer's, this work paves the way for more personalized risk assessment and therapeutic strategies.

References

1. Guo J, Huang X, Dou L, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduction and Targeted Therapy. 2022. doi:10.1038/s41392-022-01251-0

2. Andrade-Guerrero J, Santiago-Balmaseda A, Jeronimo-Aguilar P, et al. Alzheimer’s Disease: An Updated Overview of Its Genetics. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043754

3. Patel M, Cetin A, Johnson M, et al. Identification of genetic modifiers influencing disease risk in autosomal dominant Alzheimer disease mutation carriers. Alzheimer's & Dementia. 2025. doi:10.1002/alz70855_105550

4. Limorenko G, Lashuel HA. Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies. Chemical Society Reviews. 2021. doi:10.1039/d1cs00127b